RDUS
Radius Health, Inc. [RDUS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RDUS Stock Summary
Top 10 Correlated ETFs
RDUS
Top 10 Correlated Stocks
RDUS
In the News
RDUS Financial details
Company Rating
Buy
Market Cap
485.25M
Income
-25.97M
Revenue
2.96B
Book val./share
33.29
Cash/share
0.16
Dividend
0.56
Dividend %
2.06%
Employees
293
Optionable
No
Shortable
Yes
Earnings
09 Aug 2022
P/E
73.88
Forward P/E
-
PEG
-6.41
P/S
0.25
P/B
0.82
P/C
116.31
P/FCF
24.91
Quick Ratio
0.88
Current Ratio
1.93
Debt / Equity
0.5
LT Debt / Equity
0.42
-
-
EPS (TTM)
-0.92
EPS next Y
-
EPS next Q
-
EPS this Y
-115.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-20.46%
Revenue last 5Y
75.46%
Revenue Q/Q
-6.27%
EPS Q/Q
-30.43%
-
-
-
-
SMA20
-5.26%
SMA50
-28%
SMA100
-28%
Inst Own
0.22%
Inst Trans
0%
ROA
1%
ROE
1%
ROC
0.02%
Gross Margin
10%
Oper. Margin
1%
Profit Margin
-
Payout
204%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
17.0-36.64
52W High
-48.31%
52W Low
+9.47%
RSI
46
Rel Volume
0.31
Avg Volume
213.81K
Volume
66.68K
Perf Week
2.08%
Perf Month
-3.77%
Perf Quarter
-23.82%
Perf Half Y
-29.21%
-
-
-
-
Beta
0.51647
-
-
Volatility
0.59%, 1.05%
Prev Close
-0.53%
Price
18.61
Change
1.97%
RDUS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-08-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-08-31 | 2021-08-31 | 2022-08-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.19 | 3.77 | 61.88 | 98.58 | 124.12 | |
| Net income per share | -4.88 | -2.89 | -0.15 | 5.9 | 6.01 | |
| Operating cash flow per share | -4.51 | -1.79 | 4.5 | 6.79 | 8.46 | |
| Free cash flow per share | -4.52 | -1.79 | 1.54 | 2.54 | 3.12 | |
| Cash per share | 5.21 | 3.5 | 1.49 | 0.99 | 1.56 | |
| Book value per share | 1.34 | -0.92 | 24.45 | 29.87 | 33.97 | |
| Tangible book value per share | 1.17 | -1.06 | 15.76 | 20.67 | 20.07 | |
| Share holders equity per share | 1.34 | -0.92 | 24.45 | 29.87 | 33.97 | |
| Interest debt per share | 4.46 | 4.83 | 8.6 | 7.68 | 13.55 | |
| Market cap | 977.43M | 997.85M | 546.25M | 1.32B | 927.9M | |
| Enterprise value | 1.28B | 1.21B | 757.78M | 1.51B | 1.26B | |
| P/E ratio | -4.42 | -7.5 | -131.78 | 8.02 | 5.5 | |
| Price to sales ratio | 9.85 | 5.76 | 0.32 | 0.48 | 0.27 | |
| POCF ratio | -4.77 | -12.11 | 4.38 | 6.97 | 3.9 | |
| PFCF ratio | -4.77 | -12.11 | 12.83 | 18.59 | 10.6 | |
| P/B Ratio | 16.12 | -23.6 | 0.81 | 1.58 | 0.97 | |
| PTB ratio | 16.12 | -23.6 | 0.81 | 1.58 | 0.97 | |
| EV to sales | 12.85 | 7.01 | 0.44 | 0.55 | 0.36 | |
| Enterprise value over EBITDA | -6.5 | -11.42 | 35.32 | 7.03 | 5.54 | |
| EV to operating cash flow | -6.23 | -14.74 | 6.08 | 7.92 | 5.28 | |
| EV to free cash flow | -6.22 | -14.74 | 17.79 | 21.15 | 14.34 | |
| Earnings yield | -0.23 | -0.13 | -0.01 | 0.12 | 0.18 | |
| Free cash flow yield | -0.21 | -0.08 | 0.08 | 0.05 | 0.09 | |
| Debt to equity | 2.97 | -4.68 | 0.34 | 0.25 | 0.39 | |
| Debt to assets | 0.63 | 0.9 | 0.19 | 0.14 | 0.2 | |
| Net debt to EBITDA | -1.52 | -2.04 | 9.86 | 0.85 | 1.45 | |
| Current ratio | 5.92 | 3.31 | 1.62 | 1.54 | 1.76 | |
| Interest coverage | -9.09 | -4.61 | 0.79 | 40.44 | 26.46 | |
| Income quality | 0.92 | 0.62 | -56.64 | 1.12 | 1.38 | |
| Dividend Yield | 0 | 0 | 0.04 | 0.02 | 0.02 | |
| Payout ratio | 0 | 0 | -5.04 | 0.13 | 0.13 | |
| Sales general and administrative to revenue | 1.86 | 0.88 | 0.08 | 0 | 0 | |
| Research and developement to revenue | 1.01 | 0.67 | 0.09 | 0.05 | 0 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.19 | 0.17 | 0.2 | |
| Capex to operating cash flow | 0 | 0 | -0.66 | -0.63 | -0.63 | |
| Capex to revenue | 0 | 0 | -0.05 | -0.04 | -0.04 | |
| Capex to depreciation | -0.06 | 0 | -1.41 | -2.03 | -2 | |
| Stock based compensation to revenue | 0.29 | 0.14 | 0.01 | 0.01 | 0.01 | |
| Graham number | 12.12 | 7.73 | 9.08 | 62.97 | 67.78 | |
| ROIC | -0.87 | -0.71 | 0.01 | 0.15 | 0.12 | |
| Return on tangible assets | -0.79 | -0.63 | 0 | 0.13 | 0.12 | |
| Graham Net | 0.57 | -1.75 | -11.76 | -12.08 | -17.39 | |
| Working capital | 228.6M | 141.8M | 138.97M | 190.26M | 289.81M | |
| Tangible asset value | 53.25M | -48.86M | 440.73M | 582.43M | 589.8M | |
| Net current asset value | 48.7M | -58.37M | -186.86M | -111.47M | -196.74M | |
| Invested capital | 2.97 | -4.68 | 0.34 | 0.25 | 0.39 | |
| Average receivables | 10.6M | 20.02M | 81.22M | 176.62M | 225.88M | |
| Average payables | 4.07M | 5.13M | 56.35M | 143.3M | 198.8M | |
| Average inventory | 5.29M | 5.77M | 81.3M | 206.85M | 285.81M | |
| Days sales outstanding | 61.64 | 49.05 | 29.66 | 28.33 | 24.88 | |
| Days payables outstanding | 183.06 | 136.83 | 25.89 | 28.49 | 26.51 | |
| Days of inventory on hand | 269.01 | 120.79 | 38.17 | 40.6 | 38.38 | |
| Receivables turnover | 5.92 | 7.44 | 12.31 | 12.88 | 14.67 | |
| Payables turnover | 1.99 | 2.67 | 14.1 | 12.81 | 13.77 | |
| Inventory turnover | 1.36 | 3.02 | 9.56 | 8.99 | 9.51 | |
| ROE | -3.65 | 3.15 | -0.01 | 0.2 | 0.18 | |
| Capex per share | 0 | 0 | -2.96 | -4.25 | -5.35 |
Quarterly Fundamentals Overview
Last date of statement is 2023-05-31 for Q2
| Metric | History | 2022-06-30 | 2022-08-31 | 2022-11-30 | 2023-02-28 | 2023-05-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.22 | 32.11 | 21.6 | 26.92 | 28.8 | |
| Net income per share | -0.37 | 0.37 | -0.64 | 0.16 | 0.48 | |
| Operating cash flow per share | 0.02 | 6.45 | -2.24 | 3.13 | -0.75 | |
| Free cash flow per share | 0.02 | 4.58 | -3.96 | 2.17 | -1.7 | |
| Cash per share | 1.52 | 1.57 | 0.13 | 0.41 | 0.16 | |
| Book value per share | -5.75 | 34.25 | 33.36 | 32.94 | 33.29 | |
| Tangible book value per share | -5.84 | 20.24 | 18.24 | 18.06 | 18.29 | |
| Share holders equity per share | -5.75 | 34.25 | 33.36 | 32.94 | 33.29 | |
| Interest debt per share | 7.26 | 13.46 | 17.31 | 15.27 | 16.88 | |
| Market cap | 1.56B | 920.26M | 951.73M | 917.97M | 773.42M | |
| Enterprise value | 1.83B | 1.25B | 1.42B | 1.33B | 1.24B | |
| P/E ratio | -22.21 | 22.22 | -13.38 | 52.72 | 14.37 | |
| Price to sales ratio | 26.81 | 1.03 | 1.59 | 1.21 | 0.96 | |
| POCF ratio | 1.46K | 5.12 | -15.31 | 10.45 | -36.55 | |
| PFCF ratio | 1.78K | 7.22 | -8.68 | 15.09 | -16.14 | |
| P/B Ratio | -5.72 | 0.96 | 1.03 | 0.99 | 0.83 | |
| PTB ratio | -5.72 | 0.96 | 1.03 | 0.99 | 0.83 | |
| EV to sales | 31.41 | 1.4 | 2.38 | 1.76 | 1.53 | |
| Enterprise value over EBITDA | -244.68 | 77.14 | -76.59 | 143.49 | 46.94 | |
| EV to operating cash flow | 1.71K | 6.95 | -22.93 | 15.14 | -58.52 | |
| EV to free cash flow | 2.09K | 9.79 | -12.99 | 21.86 | -25.84 | |
| Earnings yield | -0.01 | 0.01 | -0.02 | 0 | 0.02 | |
| Free cash flow yield | 0 | 0.14 | -0.12 | 0.07 | -0.06 | |
| Debt to equity | -1.25 | 0.39 | 0.52 | 0.46 | 0.5 | |
| Debt to assets | 2.2 | 0.2 | 0.26 | 0.24 | 0.25 | |
| Net debt to EBITDA | -35.81 | 20.27 | -25.43 | 44.47 | 17.62 | |
| Current ratio | 1.67 | 1.76 | 2.05 | 1.85 | 1.93 | |
| Interest coverage | -1.62 | 5.28 | -4.91 | 1.74 | 5.35 | |
| Income quality | -0.08 | 16.26 | 3.54 | 20.56 | -1.55 | |
| Dividend Yield | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0 | 0.49 | -0.31 | 1.18 | 0.4 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.45 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.03 | 0.2 | 0.21 | 0.22 | 0.21 | |
| Capex to operating cash flow | -0.18 | -0.29 | 0.76 | -0.31 | 1.26 | |
| Capex to revenue | 0 | -0.06 | -0.08 | -0.04 | -0.03 | |
| Capex to depreciation | -0.49 | -2.55 | -2.22 | -1.21 | -1.19 | |
| Stock based compensation to revenue | 0.09 | 0 | 0 | 0 | 0 | |
| Graham number | 6.91 | 16.92 | 21.94 | 10.72 | 18.94 | |
| ROIC | -0.16 | 0.01 | -0.01 | 0.01 | 0.01 | |
| Return on tangible assets | -0.12 | 0.01 | -0.01 | 0 | 0.01 | |
| Graham Net | -6.83 | -17.54 | -20 | -18.42 | -19.55 | |
| Working capital | 58.55M | 289.81M | 325.56M | 272.28M | 317.22M | |
| Tangible asset value | -277.99M | 589.8M | 540.99M | 542.81M | 548.33M | |
| Net current asset value | -281.43M | -196.74M | -259.55M | -259.17M | -267.46M | |
| Invested capital | -1.25 | 0.39 | 0.52 | 0.46 | 0.5 | |
| Average receivables | 31.15M | 134.83M | 227.92M | 229.41M | 269.04M | |
| Average payables | 15.14M | 116.09M | 201.43M | 198.88M | 211.2M | |
| Average inventory | 12.89M | 163.84M | 330.19M | 315.97M | 292.86M | |
| Days sales outstanding | 49.43 | 23.91 | 32.8 | 28.65 | 33.07 | |
| Days payables outstanding | 233.8 | 24.2 | 30.3 | 28.02 | 26.46 | |
| Days of inventory on hand | 201.61 | 35.04 | 56.49 | 37.79 | 37.7 | |
| Receivables turnover | 1.82 | 3.76 | 2.74 | 3.14 | 2.72 | |
| Payables turnover | 0.38 | 3.72 | 2.97 | 3.21 | 3.4 | |
| Inventory turnover | 0.45 | 2.57 | 1.59 | 2.38 | 2.39 | |
| ROE | 0.06 | 0.01 | -0.02 | 0 | 0.01 | |
| Capex per share | 0 | -1.87 | -1.71 | -0.96 | -0.95 |
RDUS Frequently Asked Questions
What is Radius Health, Inc. stock symbol ?
Radius Health, Inc. is a US stock , located in Waltham of Massachusetts and trading under the symbol RDUS
What is Radius Health, Inc. stock quote today ?
Radius Health, Inc. stock price is $18.61 today.
Is Radius Health, Inc. stock public?
Yes, Radius Health, Inc. is a publicly traded company.
Company Profile
- Volume Average 213.81K
- Market Capitalization 485.25M
- Employee 293
- CEO Mr. Jesper Hoiland
- Headquarters Waltham,MASSACHUSETTS,US
- IPO Date 2014-06-06
-
Website
https://radiuspharm.com 
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
